Monash University update on Ivermectin research

Monash University research into Ivermectin as a potential treatment for COVID-19 is being undertaken by Dr Kylie Wagstaff from the Monash Biomedicine Discovery Institute.

Since her team's initial publication showing that Ivermectin could prevent SARS-CoV-2 infection in cells in the laboratory, funding has been secured to undertake additional preclinical tests to better understand the dosing regimen most effective under laboratory conditions.

The findings from this work are now being prepared for submission to a peer-reviewed scientific journal. Monash University is not in a position to communicate on the outcome of this work until it has been subject to rigorous peer review. The pre-clinical laboratory-based findings will be communicated when the research is peer-reviewed and accepted for publication.

Alongside this work, Dr Wagstaff has been working to establish a blinded and randomised clinical trial.   The low numbers of COVID cases in Australia in 2020 meant the planned trial in Australia had to be paused. The establishment of a trial depends on Australian and overseas circumstances, and will be communicated when we are in a position to do so.

Dr Wagstaff remains committed to undertaking a trial that will provide a definitive answer to whether or not Ivermectin is a potential treatment for COVID-19.

We note as per the advice issued from the National COVID-19 clinical evidence taskforce, Ivermectin is not to be used for the treatment of COVID-19 outside clinical trials with appropriate ethical approval.

Established in March 2020, the Taskforce is a collaboration of 32 of Australia’s peak medical colleges and health bodies who came together to provide trustworthy, evidence-based guidance for Australian clinicians caring for patients with COVID-19.

Using a 'living evidence' model, recommendations are developed by over 250 of Australia’s leading clinical experts using the latest global literature. All recommendations are then approved with a 100% consensus model by the 32 member organisations.

Learn more about the National COVID-19 Clinical Evidence Taskforce or find out more about the Taskforce's recommendations about Ivermectin.

We thank you for your ongoing interest in this work.


About the Monash Biomedicine Discovery Institute at Monash University

Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

MEDIA ENQUIRIES

Media
Monash University
T: +61 3 9903 4840
E: media@monash.edu